STCube Inc
STCube, Inc., a biopharmaceutical company, develops therapies to treat novel immune evasion mechanisms in cancer in South Korea. Its platforms include STGlyTarget that is used for the identification and development of immunomodulatory proteins; Immunomodulator Discovery Platform, a proprietary technology to screen for immunomodulatory proteins; Glyco-Specific Antibody Development Platform, a tech… Read more
STCube Inc (052020) - Total Liabilities
Latest total liabilities as of September 2025: ₩15.81 Billion KRW
Based on the latest financial reports, STCube Inc (052020) has total liabilities worth ₩15.81 Billion KRW as of September 2025.
Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities.
STCube Inc - Total Liabilities Trend (2009–2024)
This chart illustrates how STCube Inc's total liabilities have evolved over time, based on quarterly financial data. Explore and compare other companies by total liabilities.
STCube Inc Competitors by Total Liabilities
The table below lists competitors of STCube Inc ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
ADC Therapeutics SA
NYSE:ADCT
|
USA | $527.94 Million |
|
34Q0
F:34Q0
|
Germany | €555.19K |
|
Sgis Songshan Co Ltd
SHE:000717
|
China | CN¥12.16 Billion |
|
Hunan Fangsheng Pharm Co Ltd
SHG:603998
|
China | CN¥1.28 Billion |
|
IntelliEPI Cayman
TWO:4971
|
Taiwan | NT$105.65 Million |
|
LANXESS Aktiengesellschaft
PINK:LNXSY
|
USA | $4.28 Billion |
|
Merida Industry Co Ltd
TW:9914
|
Taiwan | NT$16.65 Billion |
Liability Composition Analysis (2009–2024)
This chart breaks down STCube Inc's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 35.53 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.20 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.17 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how STCube Inc's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for STCube Inc (2009–2024)
The table below shows the annual total liabilities of STCube Inc from 2009 to 2024.
| Year | Total Liabilities | Change |
|---|---|---|
| 2024-12-31 | ₩17.63 Billion | +65.54% |
| 2023-12-31 | ₩10.65 Billion | +8.11% |
| 2022-12-31 | ₩9.85 Billion | +1.58% |
| 2021-12-31 | ₩9.70 Billion | -32.79% |
| 2020-12-31 | ₩14.43 Billion | -38.77% |
| 2019-12-31 | ₩23.56 Billion | +18.32% |
| 2018-12-31 | ₩19.91 Billion | +171.44% |
| 2017-12-31 | ₩7.34 Billion | -36.40% |
| 2016-12-31 | ₩11.54 Billion | +370.34% |
| 2015-12-31 | ₩2.45 Billion | -74.73% |
| 2014-12-31 | ₩9.70 Billion | -41.65% |
| 2013-12-31 | ₩16.63 Billion | +237.74% |
| 2012-12-31 | ₩4.92 Billion | -9.52% |
| 2011-12-31 | ₩5.44 Billion | +35.83% |
| 2010-12-31 | ₩4.01 Billion | +19.03% |
| 2009-12-31 | ₩3.37 Billion | -- |